Watch ABEO. Know when insiders buy.
One email the day a filing lands. Free.
Work order
43
WATCH · insiders 46, shorts 39
Insiders, 90 days
−$88K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $339.1MP/E —DIV YIELD —FCF YIELD -24.04%REV TTM $25.5MNET INCOME −$62.9M −209.9%NET CASH $41.2M52W 4.17 – 7.46SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $11.4M | +2745.0% | 63.3% | −$13.7M | −$20.2M | −118.6% | -0.35 | −$17.5M | $479K | −$18M | Aug 13 |
| Q1 2026 · Mar 31 | $8.7M | — | 69.1% | −$23M | −$17.1M | — | -0.30 | −$19.8M | $935K | −$20.7M | May 13 |
| Q4 2025 · Dec 31derived | $5.4M | — | 80.7% | −$22.9M | −$20.5M | — | -0.34 | −$18M | $1.2M | −$19.1M | Mar 17 |
| Q3 2025 · Sep 30 | $0 | — | — | −$24M | −$5.2M | — | -0.10 | −$21.2M | $2.5M | −$23.7M | Nov 12 |
| Q2 2025 · Jun 30 | $400K | — | — | −$22.8M | $108.8M | +1369.5% | 1.71 | −$18.8M | $2.9M | −$21.7M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$19.7M | −$12M | — | -0.24 | −$18.4M | $1.4M | −$19.8M | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.7M | −$9.3M | — | -0.14 | −$16.6M | $606K | −$17.2M | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$15.3M | −$30.3M | — | -0.63 | −$12.2M | $404K | −$12.6M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$17.9M | $7.4M | — | -0.26 | −$12.7M | $711K | −$13.4M | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$14.3M | −$31.6M | — | -1.16 | −$14.5M | $725K | −$15.3M | May 15 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$13.2M | −$16.6M | — | -0.64 | −$9.2M | $37K | −$9.3M | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$11.3M | −$11.8M | — | -0.48 | −$5.7M | $44K | −$5.8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $5.8M | 73.7% | −$89.4M | $71.2M | 1223.1% | 1.01 | −$76.3M | $8M | −$84.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$64.2M | −$63.7M | — | -1.55 | −$56M | $2.4M | −$58.5M | — | — |
| FY2023 · to Dec 31 | $3.5M | — | −$47.1M | −$54.2M | -1548.2% | -2.53 | −$37M | $331K | −$37.3M | — | — |
| FY2022 · to Dec 31 | $1.4M | — | −$50.9M | −$39.7M | -2807.4% | -5.53 | −$43.5M | $130K | −$43.6M | — | — |
| FY2021 · to Dec 31 | $3M | — | −$89.8M | −$84.9M | -2831.2% | -0.86 | −$65.7M | $4.2M | −$69.8M | — | — |
| FY2020 · to Dec 31 | $10M | — | −$81.4M | −$84.2M | -842.3% | -0.91 | −$35M | $1.3M | −$36.4M | — | — |
Every number comes from ABEONA THERAPEUTICS INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.